Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Kymera Therapeutics, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
KYMR
Nasdaq
2830
www.kymeratx.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Kymera Therapeutics, Inc.
Kymera Therapeutics to Participate in Upcoming February Investor Conferences
- Jan 30th, 2025 12:00 pm
Kymera Provides Pipeline Objectives for 2025, Stock Gains
- Jan 15th, 2025 6:30 pm
Kymera Therapeutics (KYMR) Moves 7.8% Higher: Will This Strength Last?
- Jan 15th, 2025 2:38 pm
Kymera Therapeutics Surges 10% on Bold 2025 Roadmap to Revolutionize Immunology Treatments
- Jan 14th, 2025 6:28 pm
Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs
- Jan 14th, 2025 12:00 pm
Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14
- Jan 7th, 2025 12:00 pm
Leerink sees positive readthrough for Kymera Therapeutics from J&J-Kaken deal
- Dec 27th, 2024 9:25 pm
Kymera Therapeutics to Participate in Upcoming December Investor Conferences
- Nov 26th, 2024 12:00 pm
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
- Nov 5th, 2024 12:00 pm
Analysts Have Made A Financial Statement On Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Third-Quarter Report
- Nov 4th, 2024 10:49 am
Kymera Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
- Nov 1st, 2024 2:47 pm
Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus
- Nov 1st, 2024 2:18 pm
Kymera Therapeutics Inc (KYMR) Q3 2024 Earnings Call Highlights: Strategic Advancements and ...
- Nov 1st, 2024 7:07 am
Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Lags Revenue Estimates
- Oct 31st, 2024 12:40 pm
Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update
- Oct 31st, 2024 11:30 am
Voyager Therapeutics (VYGR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- Oct 28th, 2024 2:01 pm
Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
- Oct 24th, 2024 2:01 pm
Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases
- Oct 24th, 2024 11:00 am
Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31
- Oct 23rd, 2024 11:15 am
Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium
- Oct 23rd, 2024 11:00 am
Scroll